title: Nocardia veterana, a new emerging pathogen.
abstract: Nocardia veterana is a newly described species named after the veteran's hospital where it was first isolated. This initial type strain was not thought to be clinically significant. We describe three cases of pulmonary disease attributable to N. veterana: two cases in patients presenting with multiple pulmonary nodules in a setting of immunocompromise and one case of exacerbation of chronic pulmonary disease. The isolates were susceptible to ampicillin, imipenem, gentamicin, amikacin, and trimethoprim-sulfamethoxazole and had reduced susceptibilities to ceftriaxone, cefotaxime, minocycline, and ciprofloxacin. The MICs of amoxicillin-clavulanate were higher than that of ampicillin alone, and the bacteria produced a beta-lactamase detectable only after induction with clavulanic acid. Phenotypically, the isolates could not be characterized beyond the Nocardia genus level. All three isolates were definitively identified as N. veterana by PCR and sequencing of the 16S rRNA gene. On the basis of their susceptibility and restriction enzyme analysis profiles, our findings indicate that they could potentially be misidentified as N. nova. These cases illustrate the pathogenic potential of this newly described species and emphasize the importance of accurate identification of Nocardia isolates to the species level by integrated use of phenotypic and genotypic methods.
authors.affiliation: Department of Laboratory Medicine, University of Washington, Seattle, Washington 98195, USA.
authors.forename: Sudha
authors.initials: S
authors.lastname: Pottumarthy
authors.forename: Ajit P
authors.initials: AP
authors.lastname: Limaye
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Prentice
authors.forename: Yolanda B
authors.initials: YB
authors.lastname: Houze
authors.forename: Susan R
authors.initials: SR
authors.lastname: Swanzy
authors.forename: Brad T
authors.initials: BT
authors.lastname: Cookson
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D015373:Bacterial Typing Techniques; D002908:Chronic Disease; D021821:Communicable Diseases, Emerging / Q000382:microbiology*; D004275:DNA, Ribosomal / Q000032:analysis; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D008171:Lung Diseases / Q000150:complications; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D008969:Molecular Sequence Data; D009615:Nocardia / Q000145:classification* / Q000187:drug effects / Q000235:genetics / Q000472:pathogenicity; D009617:Nocardia Infections / Q000382:microbiology*; D016133:Polymerase Chain Reaction; D012336:RNA, Ribosomal, 16S / Q000235:genetics
chemical_list: D000900:Anti-Bacterial Agents; D004275:DNA, Ribosomal; D012336:RNA, Ribosomal, 16S